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Abstract
Aerobic glycolysis in cancer cells is regulated by multiple effectors that include Akt and pyruvate kinase M2 (PKM2). Mucin 1
(MUC1) is a heterodimeric glycoprotein that is aberrantly overexpressed by human breast and other carcinomas. Here we
show that transformation of rat fibroblasts by the oncogenic MUC1-C subunit is associated with Akt-mediated increases in
glucose uptake and lactate production, consistent with the stimulation of glycolysis. The results also demonstrate that the
MUC1-C cytoplasmic domain binds directly to PKM2 at the B- and C-domains. Interaction between the MUC1-C cytoplasmic
domain Cys-3 and the PKM2 C-domain Cys-474 was found to stimulate PKM2 activity. Conversely, epidermal growth factor
receptor (EGFR)-mediated phosphorylation of the MUC1-C cytoplasmic domain on Tyr-46 conferred binding to PKM2 Lys-
433 and inhibited PKM2 activity. In human breast cancer cells, silencing MUC1-C was associated with decreases in glucose
uptake and lactate production, confirming involvement of MUC1-C in the regulation of glycolysis. In addition, EGFR-
mediated phosphorylation of MUC1-C in breast cancer cells was associated with decreases in PKM2 activity. These findings
indicate that the MUC1-C subunit regulates glycolysis and that this response is conferred in part by PKM2. Thus, the
overexpression of MUC1-C oncoprotein in diverse human carcinomas could be of importance to the Warburg effect of
aerobic glycolysis.
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Introduction
Cancer cells are distinguished from their normal counterparts
by metabolic differences that include increased utilization of
glucose by aerobic glycolysis. This characteristic of malignant cells,
known as the Warburg effect, associates a high rate of glucose
consumption with enhanced lactate production in the presence of
oxygen [1]. Aerobic glycolysis in cancer cells has been linked with
increased expression of glycolytic genes [2,3]. Pyruvate kinase (PK)
is one of the upregulated glycolytic gene products that catalyzes
the production of pyruvate and ATP from phosphoenolpyruvate
(PEP) and ADP. There are four PK isoenzymes, M1, M2, L and
R. The M1 isoform is expressed in most adult cells. The M2
isoform (PKM2), a splice variant of M1, is found in embryonic
cells, certain normal proliferating cells and cancer cells [4].
Heterogenous nuclear ribonucleoproteins bind to PKM1 mRNA
and inhibit its splicing [5]. Converting PKM2 expression to PKM1
in cancer cells reverses the Warburg effect and is associated with
loss of tumorigenicity, establishing the importance of PKM2 for
aerobic glycolysis and the proliferation of malignant cells [6]. The
distinct region of PKM2, as compared to PKM1, functions in the
allosteric activation of the enzyme by fructose-1,6-bisphosphate
(FBP) [7] and its inactivation by phosphotyrosine containing
proteins [8,9]. Under these circumstances, the regulation of
PKM2 activity dictates the metabolism of glucose to pyruvate,
which is converted by lactate dehydrogenase (LDH) to lactate or is
utilized by the mitochondrial tricarboxylic acid (TCA) cycle [10].
These findings have thus supported the need to more fully
understand the signals that regulate aerobic glycolysis and PKM2
activity in malignant cells.
The mucin 1 (MUC1) protein is overexpressed in most human
carcinomas and certain hematologic malignancies, making it one
of the more common alterations in human cancers [11]. MUC1 is
expressed as two subunits that form a heterodimer at the cell
membrane. The large MUC1 N-terminal subunit (MUC1-N) is
positioned extracellularly and contains the glycosylated tandem
repeats that are characteristic of the mucin family. The MUC1 C-
terminal subunit (MUC1-C) spans the cell membrane and contains
a 58 amino acid extracellular domain and a 72 amino acid
cytoplamic domain [11]. The MUC1-C extracellular domain
interacts with galectin-3 and thereby forms complexes at the cell
surface with the epidermal growth factor receptor (EGFR) [12].
Activation of EGFR is in turn associated with phosphorylation of
the MUC1-C cytoplasmic domain [11]. Significantly, overexpres-
sion of the MUC1-C subunit, and specifically the cytoplasmic
domain, is sufficient to induce anchorage-independent growth and
tumorigenicity [13,14]. With overexpression of MUC1 in cancer
cells, the MUC1-C subunit accumulates in the cytoplasm and is
targeted to the nucleus, where it contributes to the regulation of
gene expression [11]. In this regard, MUC1-C-induced transfor-
mation is associated with the activation of genes involved with
proliferation and tumorigenesis [15,16]. MUC1-C also induces a
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genes that regulate cholesterol and fatty acid synthesis [17]. Other
studies have demonstrated that MUC1-C activates the PI3K-
.Akt pathway [18,19], which in turn stimulates activity of the
glycolytic enzymes, hexokinase and phosphofructose kinase. There
is, however, no known link between MUC1-C and the glycolytic
pathway.
The present studies demonstrate that MUC1-C is involved in
the regulation of glucose uptake and lactate production in MUC1-
C-induced transformation of rat fibroblasts and in human breast
cancer cells. The results also demonstrate that the MUC1-C
cytoplasmic domain interacts directly with PKM2 and regulates
PKM2 activity. The MUC1-C cytoplasmic domain contains a Cys
residue that binds to the PKM2 C-domain Cys-474 and stimulates
PKM2 activity. By contrast, the EGFR-phosphorylated MUC1-C
cytoplasmic domain interacts with the PKM2 C-domain at Lys-
433 and inhibits PKM2. These findings indicate that the
overexpression of MUC1-C in cancer cells contributes to the
regulation of aerobic glycolysis.
Results
MUC1-C-induced transformation is associated with the
induction of aerobic glycolysis
The MUC1-C subunit consists of a 58 amino acid (aa)
extracellular domain, a 28 aa transmembrane domain and a 72 aa
cytoplasmic domain (Fig. 1A). Expression of the MUC1-C
cytoplasmic domain (MUC1-CD) in 3Y1 fibroblasts is associated
with the induction of colony formation in soft agar and tumor
formation in nude mice[13,14]. In the present studies, we found that
MUC1-CD-inducedtransformationof3Y1cellsisassociatedwithan
increase in glucose uptake (Fig. 1B) and lactate production (Fig. 1C),
consistent withthe stimulation of glycolysis.Toassess,at leastin part,
the basis for this response, studies were performed to determine
effects on PKM2. Notably, there was a significant increase in PKM2
activity in the MUC1-CD transformed 3Y1 fibroblasts (Fig. 1D).
3Y1/vector cells express PKM2, but not PKM1, and MUC1-CD-
induced transformation had no apparent effect on PKM2 levels
(Fig. 1E). Other studies have shown that PKM2 activity is inhibited
by phosphorylation on Tyr-105 in certain cancer cells [9]. MUC1-
CD-inducedtransformationwasnotassociatedwithachangeinTyr-
105 phosphorylation (Fig. 1F). In addition, there was no apparent
cellular redistribution of PKM2 as determined by confocal
microscopy (Fig. S1). Previous studies have demonstrated that Akt
activation as determined by phosphorylation at Ser-473 is increased
in 3Y1/MUC1-CD cells as compared to that found in 3Y1/vector
cells [18]. To assess whether the increase in p-Akt is responsible for
the activation of PKM2, we silenced Akt in the 3Y1/vector and
3Y1/MUC1-CD cells (Fig. 1G) and measured glucose uptake,
lactate production and PKM2 activity. The results demonstrate that
silencing Akt decreases glucose uptake in both 3Y1/vector and 3Y1/
MUC1-CD cells (Fig. 1H, left). Moreover, silencing Akt in the 3Y1/
vector and 3Y1/MUC1-CD cells was associated with partial
decreases in lactate production (Fig. 1H, right). By contrast, silencing
Akt had little if any effect on PKM2 activity in the 3Y1/MUC1-CD
cells (Fig. 1I), indicating that MUC1-CD-mediated induction of
PKM2 is not dependent on Akt activation.
MUC1-C cytoplasmic domain Cys-3 residue interacts with
PKM2
To determine whether MUC1-CD interacts with PKM2 and
thereby affects its activity, coimmunoprecipitation studies were
performed with 3Y1/MUC1-CD cell lysates. Analysis of anti-
PKM2 precipitates by immunoblotting with anti-MUC1-C
supported the association of these proteins (Fig. 2A). In GST
pull-down experiments, incubation of 3Y1/vector cell lysates with
GST and GST-MUC1-CD provided further support for an
interaction between PKM2 and MUC1-CD (Fig. 2B). To extend
these observations to cells that express endogenous MUC1,
coimmunoprecipitation studies were performed on lysates from
human ZR-75-1 breast cancer cells. Here, PKM2 was detectable
in complexes with the 25–20 kDa MUC1-C subunit (Fig. 2C).
Pull-down experiments with ZR-75-1 cell lysates also demonstrat-
ed binding of MUC1-CD to PKM2 (Fig. 2D). Studies with
MUC1-CD deletion mutants further showed that the association
with PKM2 is conferred by MUC1-CD(1–45) and not MUC1-
CD(46–72) (Fig. 2D). Incubation of GST-MUC1-CD with
purified recombinant His-tagged PKM2 confirmed direct binding
of MUC1-CD and PKM2 (Fig. 2E). The results also showed that
MUC1-CD(1–45) and not MUC1-CD(46–72) is responsible for
the direct interaction (Fig. 2E). MUC1-CD contains a CQC motif
(aa 1–3) that contributes to the formation of MUC1-C
homodimers (Fig. 1A) [20]. Mutation of the CQC motif to AQA
(C1A/C3A) blocked binding of MUC1-CD to PKM2 (Fig. 2F).
Binding of MUC1-CD to PKM2 was also abrogated with the
C3A, and not the C1A, mutant, indicating that Cys-3 is
responsible for the interaction (Fig. 2F). These findings indicate
that MUC1-C associates with PKM2 in cells through a direct
interaction mediated by the MUC1-C cytoplasmic domain Cys-3
residue.
MUC1-CD binds directly to the PKM2 B-domain Cys-165
and C-domain Cys-474
PKM2 consists of an N-terminus (aa 1–43), A1-domain (aa 44–
116), B-domain (aa 117–218), A2-domain (aa 219–389) and C-
domain (aa 390–531) [7] (Fig. 3A). Binding of MUC1-CD was
detectable with PKM2(1–218) and PKM2(390–531), but not with
PKM2(219–389) (Fig. 3B). Further analysis with PKM2(1–218)
deletion mutants demonstrated that MUC1-CD binds directly to
the B-domain (aa 117–218) and not the N-terminus (aa 1–43) or
A1-domain (aa 44–116) (Fig. 3C). The PKM2 B-domain contains
two cysteines at positions 152 and 165. Mutation of PKM2(117–
218) Cys-152 to Ala (C152A) had no effect on the interaction with
MUC1-CD (Fig. 3D, left). By contrast, binding of MUC1-CD and
PKM2(117-218) was abrogated by mutating Cys-165 to Ala
(C165A) (Fig. 3D, right). With regard to the PKM2 C-domain (aa
390–531), Cys residues are located at positions 423, 424 and 474.
Binding of MUC1-CD to PKM2(390–531) was not affected by
mutating Cys-423 to Ala (C423A) (Fig. 3E, left) or Cys-424 to Ala
(C424A) (Fig. 3E, middle). However, the interaction with MUC1-
CD was attenuated by mutation of the PKM2(390–531) Cys-474
residue to Ala (C474A) (Fig. 3E, right). These findings indicate that
the MUC1-CD Cys-3 residue binds directly to (i) the PKM2 B-
domain Cys-165, and (ii) the PKM2 C-domain Cys-474.
Phosphorylated MUC1-CD binds to the PKM2 C-domain
Lys-433
The MUC1-C cytoplasmic domain is phosphorylated on Tyr-
46 by EGFR (Fig. 1A) [21]. Other studies have demonstrated that
certain phosphotyrosine peptides interact with the PKM2 C-
domain and inhibit its activity [8]. To determine whether tyrosine
phosphorylated MUC1-C cytoplasmic domain binds to PKM2,
we first incubated MUC1-CD and MUC1-CD(Y46F) with EGFR
and ATP. Analysis of the reaction products by immunoblotting
with anti-P-Tyr confirmed phosphorylation on Tyr-46 (Fig. 4A,
left). As found with MUC1-CD, incubation of p-MUC1-CD with
the PKM2 deletion mutants demonstrated binding to PKM2(1-
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CD was also detectable with PKM2(390-531/C474A) (Fig. 4B),
supporting an interaction that is not mediated by the PKM2 Cys-
474 residue. To extend these observations, the MUC1-CD(C3A)
mutant, which is devoid of binding to PKM2, was subjected to
EGFR phosphorylation. Comparison of MUC1-CD(C3A) and p-
MUC1-CD(C3A) confirmed that EGFR phosphorylation induces
binding to PKM2(390–531) (Fig. 4C). These results were also
confirmed in experiments in which binding of full-length PKM2
was detectable with p-MUC1-CD(C3A) and not MUC1-CD(C3A)
(Fig. 4D). The PKM2 C-domain contains a Lys-433 residue that is
essential for phosphotyrosine peptide binding [8]. Indeed,
mutation of PKM2(390–531) Lys-433 to glutamate (K433E)
partially decreased binding of p-MUC1-CD (Fig. 4E). Incubation
Figure 1. MUC1-C cytoplasmic domain (MUC1-CD)-induced transformation of 3Y1 cells is associated with induction of glycolysis
and PKM2 activity. A. Structure of the MUC1-C subunit with the extracellular domain (ED), transmembrane domain (TM) and amino acid sequence
of the cytoplasmic domain (MUC1-CD). The CQC motif and the EGFR phosphorylation site are highlighted. B and C. 3Y1/vector and 3Y1/MUC1-CD
cells were analyzed for glucose uptake (B) and lactate production (C). The results (mean6SD of five separate experiments each performed in
triplicate) are expressed as nmol/10
6 cells. D. Lysates from rat 3Y1/vector and 3Y1/MUC1-CD cells were analyzed for PKM2 activity. The results
(mean6SD of three separate experiments each performed in triplicate) are expressed as relative PKM2 activity compared to that obtained in 3Y1/
vector cells (assigned a value of 1). The student’s t-test was used to determine the p-values. E and F. Lysates from 3Y1/vector and 3Y1/MUC1-CD cells
were immunoblotted with the indicated antibodies. G-I. 3Y1/vector and 3Y1/MUC1-CD cells were transfected with Control siRNA or Akt siRNA pools
for 72 h. Lysates from the indicated cells were immunoblotted with anti-Akt and anti-b-actin (G). The indicated cells were analyzed for glucose uptake
(H, left) and lactate production (H, right). The results (mean6SD of three replicates) are expressed as nmol/10
6 cells. Lysates from the indicated cells
were also analyzed for PKM2 activity (I). The results (mean6SD of three replicates) are expressed as relative PKM2 activity compared to that obtained
in 3Y1/vector cells (assigned a value of 1).
doi:10.1371/journal.pone.0028234.g001
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PLoS ONE | www.plosone.org 3 November 2011 | Volume 6 | Issue 11 | e28234Figure 2. MUC1-C cytoplasmic domain binds to PKM2. A. Lysates from 3Y1/MUC1-CD cells were subjected to immunoprecipitation with a
control IgG or anti-PKM2. The precipitates were immunoblotted with the indicated antibodies. B. Lysates from 3Y1/vector cells were incubated with
GST or GST-MUC1-CD. The adsorbates to glutathione beads were immunoblotted with anti-PKM2. Input of the GST proteins was assessed by
Coomassie blue staining. C. Lysates from human ZR-75-1 breast cancer cells were immunoprecipitated with a control IgG or anti-PKM2. Precipitates
were immunoblotted with the indicated antibodies. D. ZR-75-1 cell lysates were incubated with GST, GST-MUC1-CD and the indicated GST-MUC1-CD
deletion mutants. The adsorbates were immunoblotted with anti-PKM2. Input of the GST proteins was assessed by Coomassie blue staining. E. PKM2
was incubated with GST, GST-MUC1-CD and the indicated GST-MUC1-CD deletion mutants. The adsorbates were immunoblotted with anti-PKM2. F.
PKM2 was incubated with GST, GST-MUC1-CD and the indicated GST-MUC1-CD mutants in which Cys-1 and/or Cys-3 were substituted with Ala. The
adsorbates were immunoblotted with anti-PKM2.
doi:10.1371/journal.pone.0028234.g002
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PLoS ONE | www.plosone.org 4 November 2011 | Volume 6 | Issue 11 | e28234Figure 3. MUC1-CD binds directly to PKM2 B- and C-domains. A. Schematic representation of the PKM2 protein with the N-terminus (N) and
the A1-, B-, A2- and C-domains. Highlighted are the Cys-165 and Cys-474 residues. B and C. MUC1-CD was incubated with GST and the indicated GST-
PKM2 deletion mutants. The adsorbates were immunoblotted with anti-MUC1-C. Input of the GST proteins was assessed by Coomassie blue staining.
D. MUC1-CD was incubated with GST, GST-PKM2(117-218) and GST-PKM2(117-218) with the indicated C152A and C165A mutations. The adsorbates
were immunoblotted with anti-MUC1-C. E. MUC1-CD was incubated with GST, GST-PKM2(390-531) and GST-PKM2(390–531) with the indicated
C423A, C424A and C474A mutations. The adsorbates were immunoblotted with anti-MUC1-C.
doi:10.1371/journal.pone.0028234.g003
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PKM2(390–531/K433E) further demonstrated that binding to
endogenous MUC1-C is partially decreased by the K433E
mutation (Fig. 4F). These findings demonstrate that phosphory-
lation of the MUC1-C cytoplasmic domain Tyr-46 residue confers
binding to the PKM2 C-domain at Lys-433.
Figure 4. Phosphorylation of MUC1-CD on Tyr-46 confers binding to the PKM2 C-domain at Lys-433. A. His-tagged MUC1-CD and
MUC1-CD(Y46F) were incubated with EGFR in the absence and presence of ATP. The reaction products were analyzed by immunoblotting with anti-
p-Tyr and anti-MUC1-C (left). GST and the indicated GST-PKM2 deletion mutants were incubated with EGFR-phosphorylated MUC1-CD (p-MUC1-CD)
(right). The adsorbates were immunoblotted with anti-MUC1-C. Input of the GST proteins was assessed by Coomassie blue staining. B. GST and GST-
PKM2(390–531/C474A) were incubated with MUC1-CD or p-MUC1-CD. The adsorbates were immunoblotted with anti-MUC1-C. C. GST and GST-
PKM2(390-531) were incubated with MUC1-CD(C3A) or EGFR-phosphorylated p-MUC1-CD(C3A). The adsorbates were immunoblotted with anti-
MUC1-C. D. PKM2 was incubated with GST, GST-MUC1-CD(C3A) and EGFR-phosphorylated GST-p-MUC1-CD(C3A). The adsorbates were
immunoblotted with anti-MUC1-C and anti-p-Tyr. E and F. GST, GST-PKM2(390-531) and GST-PKM2(390-531/K433E) were incubated with p-MUC1-
CD (E) or ZR-75-1 cell lysate (F). The adsorbates were immunoblotted with anti-MUC1-C.
doi:10.1371/journal.pone.0028234.g004
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PKM2 is allosterically activated by binding of FBP to the C-
domain [7]. Of potential functional significance to the interaction
between MUC1-CD and PKM2, incubation of MUC1-CD with
PKM2 was associated with a modest stimulation of PKM2 activity
(Fig. 5A, left). MUC1-CD-induced stimulation of PKM2 was
dependent on the MUC1-CD Cys-3 motif in that MUC1-
CD(C3A) had no apparent effect on PKM2 activity (Fig. 5A,
right). As shown previously [7], FBP was effective in stimulating
PKM2 activity (Fig. 5B). Moreover, the addition of both FBP and
MUC1-CD resulted in at least an additive increase (Fig. 5B),
indicating that MUC1-CD can promote FBP-induced PKM2
activation. To extend these observations, we incubated PKM2
with GO-203, a peptide that contains poly-Arg ([R]9) and the
MUC1-CD sequence CQCRRKN containing the Cys-3 residue
that was shown above to bind PKM2 (Fig. 5C). GO-203 was
highly effective in stimulating PKM2 activity, whereas a control
peptide, designated CP-2, in which the Cys-3 residue was
substituted with Ala (AQARRKN) had little effect (Fig. 5C).
Moreover, mutation of PKM2 Cys-474, but not Cys-165, to Ala
resulted in abrogation of GO-203-induced increases in PKM2
activity (Fig. 5D). Incubation of PKM2 with both FBP and GO-
Figure 5. MUC1-CD CQC motif stimulates PKM2 activity. A. Recombinant PKM2 was incubated in the absence and presence of the indicated
concentrations of MUC1-CD (left) or MUC1-CD (C3A) (right) for 30 min at room temperature. The results (mean+SD of five separate experiments) are
expressed as the relative PKM2 activity compared to that obtained with the control. B. PKM2 was incubated with the indicated concentrations of FBP
alone, MUC1-CD alone, or FBP and MUC1-CD. The results (mean+SD of three separate experiments) are expressed as the relative PKM2 activity
compared to that obtained with the control. C. Amino acid sequences of GO-203 and CP-2 peptides. PKM2 was incubated with 100 mM GO-203 or CP-
2. The results (mean+SD of five separate experiments) are expressed as the relative PKM2 activity compared to that obtained with the control. D.
PKM2 and the indicated PKM2 mutants were incubated in the absence (open bars) and presence of 100 mM GO-203 (solid bars). The results
(mean+SD of three separate experiments) are expressed as the relative PKM2 activity compared to that obtained in the absence of GO-203. E. PKM2
was incubated with the indicated concentrations of FBP alone, GO-203 alone, or FBP and GO-203. The results (mean+SD of three separate
experiments) are expressed as the relative PKM2 activity compared to that obtained with the control.
doi:10.1371/journal.pone.0028234.g005
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inducing PKM2 activity (Fig. 5E). These findings indicate that the
interaction between the MUC1-CD Cys-3 residue and PKM2
Cys-474 stimulates PKM2 activity.
Tyrosine-phosphorylated MUC1-CD inhibits PKM2
activity
Binding of tyrosine-phosphorylated peptides to the PKM2 C-
domain is associated with inhibition of PKM2 [8]. Consequently,
we compared the effects of MUC1-CD and EGFR-phosphorylated
p-MUC1-CD on PKM2 activity. As shown above, FBP-induced
stimulation of PKM2 was increased by MUC1-CD (Fig. 6A). By
comparison, phosphorylated p-MUC1-CD was ineffective in
increasing PKM2 activity (Fig. 6A). These studies with p-MUC1-
CD are, however, complicated by the potential for both stimulatory
effects of Cys-3 and inhibitory effects of p-Tyr-46. Consequently,
experiments were performed with the MUC1-CD(C3A) mutant,
which is ineffective in stimulating PKM2. Here, MUC1-CD(C3A)
had no apparent stimulatory effect and EGFR-phosphorylated
MUC1-CD(C3A) suppressed PKM2 activity (Fig. 6A). As a control,
the MUC1-CD(Y46F) mutant that had been incubated with EGFR
and ATP had little if any effect (Fig. 6A). To confirm these
observations, we synthesized peptides corresponding to the control
and EGFR-phosphorylated MUC1-CD Tyr-46 (YEKV) motif
(Fig. 6B). The phospho-Tyr-46 peptide, but not the unpho-
sphorylated form, inhibited PKM2 activity (Fig. 6C). Experiments
were also performed with GO-203 alone and in combination with
the phospho-Tyr-46 peptide. Under these experimental conditions,
GO-203-induced stimulation of PKM2 activity was unaffected by
the phospho-Tyr-46 peptide (Fig. 6D). These findings indicate that
EGFR-mediated phosphorylation of MUC1-CD on the YEKV
motif inhibits PKM2 activity and that GO-203-induced stimulation
of PKM2 is not blocked by this mechanism.
MUC1-C promotes aerobic glycolysis in breast cancer
cells
To determine whether endogenous MUC1-C affects glycolysis,
we studied ZR-75-1 and MCF-7 breast cancer cells with stable
Figure 6. PKM2 activity is inhibited by EGFR-phosphorylated MUC1-CD. A. PKM2 was incubated with 10 mM FBP in the absence (Control)
and presence of 10 mM unphosphorylated and EGFR-phosphorylated MUC1-CD, MUC1-CD(C3A) and MUC1-CD(Y46F). The results (mean+SD of three
separate experiments) are expressed as the relative PKM2 activity compared to that obtained with the control. B. Sequences of the Tyr-46 and
phospho-Tyr-46 peptides. C. PKM2 was incubated with 10 mM FBP in the absence (Control) and presence of 100 mM phospho-Tyr-46 peptide or Tyr-
46 peptide. The results (mean+SD of three separate experiments) are expressed as the relative PKM2 activity compared to that obtained with the
control. D. PKM2 was incubated in the absence (Control) and presence of 20 mM GO-203 alone, 100 mM phospho-Tyr-46 peptide alone or GO-203
with phospho-Tyr-46 peptide. The results (mean+SD of three separate experiments) are expressed as the relative PKM2 activity compared to that
obtained with the control.
doi:10.1371/journal.pone.0028234.g006
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MUC1-C had no effect on PKM2 levels or phosphorylation on
Tyr-105 (Fig. 7A). Significantly, analysis of both ZR-75-1 and
MCF-7 cells demonstrated that silencing MUC1-C is associated
with decreased glucose uptake (Fig. 7B) and decreased lactate
production (Fig. 7C), indicating that MUC1-C promotes glycolysis
in breast cancer cells. In addition to the suppression of glycolysis,
silencing MUC1-C conferred decreases in ZR-75-1 and MCF-7
colony formation (Fig. 7D).
Effects of MUC1-C on PKM2 activity in breast cancer cells
Studies were performed to determine whether the effect of
MUC1-C on aerobic glycolysis in breast cancer cells is associated
with changes in PKM2 activity. At 24 h after passage of ZR-75-1
cells, PKM2 activity was decreased with downregulation of
MUC1-C expression (Fig. 8A, left). By contrast, at 72 h of culture,
silencing MUC1-C was associated with an increase in PKM2
activity (Fig. 8A, left). These observations corresponded with an
increase in the extent of MUC1-C tyrosine phosphorylation from
24 to 72 h of culture (Fig. 8A, right). Similar results were obtained
with MCF-7 cells (Fig. 8B, left and right), indicating that the
MUC1-C tyrosine phosphorylation status contributes to the
regulation of PKM2. In that line of reasoning, studies were
performed to assess the effects of EGF stimulation. Treatment of
the MCF-7/vector cells with EGF was associated with an increase
in phosphorylation of MUC1-C on tyrosine (Fig. 8C, left).
Moreover, EGF stimulation of MCF-7/vector, but not MCF-7/
MUC1siRNA, cells resulted in downregulation of PKM2 activity
(Fig. 8C, right). These findings indicate that tyrosine phosphor-
ylated MUC1-C suppresses PKM2 activity in breast cancer cells
and that this effect is more pronounced in the response to EGF
stimulation.
Effects of expressing a MUC1(C3A) mutant on PKM2
activity
To determine whether the effects of silencing MUC1-C could
be attributed to the interaction between the MUC1-C cytoplasmic
domain and PKM2, studies were performed with HCT116 cells,
Figure 7. Silencing MUC1-C downregulates aerobic glycolysis in breast cancer cells. A. Lysates from ZR-75-1 and MCF-7 cells stably
expressing an empty vector or a MUC1siRNA were immunoblotted with the indicated antibodies. B. The indicated cells were analyzed for glucose
uptake. The results (mean6SD of three separate experiments each performed in triplicate) are expressed as nmol/10
6 cells. C. The indicated cells were
analyzed for lactate production. The results (mean6SD of three separate experiments each performed in triplicate) are expressed as relative lactate
production compared to that in cells expressing the empty vector (assigned a value of 1). D. The indicated cells were plated in soft agar and colonies
were counted after incubation for 14 days. The results (mean6SD of two separate experiments each performed in triplicate) are expressed as the
colony number relative to that obtained with ZR-75-1 or MCF-7 cells expressing an empty vector (each assigned a value of 1).
doi:10.1371/journal.pone.0028234.g007
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to express an empty vector, wild-type MUC1 or MUC1 with the
C3A mutation (Fig. 9A). MUC1 and MUC1(C3A) expression had
no effect on PKM2 or p-PKM2(Tyr-105) levels (Fig. 9A). Glucose
uptake was increased in HCT116/MUC1, but not HCT116/
MUC1(C3A), cells (Fig. 9B). Similar results were obtained when
measuring lactate production (Fig. 9C). MUC1, but not
MUC1(C3A), expression was also associated with increases in
PKM2 activity (Fig. 9D). Moreover, as shown previously [20],
MUC1 expression was associated with increases in HCT116
colony formation and this effect was abrogated by the
MUC1(C3A) mutant (Fig. 9E). These findings indicate that
blocking the interaction between MUC1-CD and PKM2 atten-
uates the MUC1-CD-mediated effects on glycolysis, PKM2
activity and colony formation.
Discussion
MUC1-C oncoprotein promotes glycolysis
Most cancer cells are dependent on aerobic glycolysis for the
generation of energy that is needed for cellular processes. This
altered metabolism, known as the Warburg effect, involves
increased uptake of glucose with decreased utilization of the
TCA cycle, such that pyruvate generated during glycolysis is
converted to lactate [22]. This metabolic switch, which generates
intermediates for cell growth, is induced by certain oncogenes
[23]. The present studies demonstrate that transformation of rat
3Y1 fibroblasts with the MUC1-C oncoprotein is associated with
increased uptake of glucose and production of lactate. Moreover,
silencing of MUC1-C in human breast cancer cells resulted in
decreased glucose uptake and lactate production, indicating that
MUC1-C contributes to aerobic glycolysis. Activation of the
PI3K-.Akt pathway has been linked to glucose metabolism
through glucose transporter expression, and stimulation of
hexokinase and phosphofructokinase activities [24]. In that sense,
MUC1-C activates the PI3K-.Akt pathway, at least in part,
through direct binding of PI3K to a consensus pYHPM motif in
the MUC1-C cytoplasmic domain [18,19]. Thus, MUC1-C could
promote aerobic glycolysis through activation of PI3K-.Akt
signaling. Indeed, silencing Akt in 3Y1/MUC1-CD cells was
associated with decreased glucose uptake and partial suppression
of lactate production, indicating that MUC1-CD may regulate
aerobic glycolysis by Akt-dependent and –independent mecha-
nisms. The present studies provide another link between MUC1-C
and aerobic glycolysis through interactions with PKM2. The
PKM2 isoform is necessary for conferring the Warburg effect and
enables cancer cells to divert glucose metabolites for the synthesis
of macromolecules in the response to growth factor stimulation
[4,6,22]. In this capacity, the regulation of PKM2 is of importance
to the metabolism of cancer cells and their ability to form tumors
[6]. However, little is known about proteins that interact with
PKM2 and affect its activity.
MUC1-C subunit associates with PKM2
Our studies demonstrate that MUC1-C binds directly to the
PKM2 B- and C-domains. A cysteine in the MUC1-C cytoplasmic
domain, designated Cys-3, interacts with the PKM2 B-domain
Cys-165, which is highly conserved in the other PK isoforms and
resides on the PKM2 surface near the hinge region that dictates
the size of the active site cleft [7] (structural model shown in Fig.
S2). To our knowledge, there are no other proteins that are known
to bind to the PKM2 B-domain. Mutation of Cys-165 had no
effect on basal or MUC1-CD Cys-3-induced PKM2 activity; thus,
further study will be needed to define the significance of this
MUC1-C interaction with the PKM2 B-domain. In this context,
the MUC1-C cytoplasmic domain forms complexes with c-Src and
c-Abl, and thereby could function as an adapter that facilitates the
association of PKM2 with these tyrosine kinases [11]. By
extension, c-Src-mediated tyrosine phosphorylation is associated
Figure 8. Effects of MUC1-C on PKM2 activity are dependent on
cell context. A and B. Lysates from the indicated ZR-75-1 (A) and MCF-
7 (B) cells harvested at the indicated times after passage were analyzed
for PKM2 activity (left). The results (mean+SD of three separate
experiments each performed in triplicate) are expressed as relative
PKM2 activity compared to that obtained in cells expressing the empty
vector (assigned a value of 1). The ZR-75-1/vector (A) and MCF-7/vector
(B) cell lysates were also incubated with anti-MUC1-C and the
precipitates were immunoblotted with the indicated antibodies (right).
C. MCF-7/vector and MCF-7/MUC1siRNA cells were left untreated and
stimulated with EGF for 5 min. Lysates from MCF-7/vector cells were
incubated with anti-MUC1-C and the precipitates were immunoblotted
with the indicated antibodies (left). Lysates were assayed for PKM2
activity (right). The results (mean+SD of three separate experiments) are
expressed as the relative PKM2 activity as compared to that in
unstimulated MCF-7/vector cells.
doi:10.1371/journal.pone.0028234.g008
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that the MUC1-C cytoplasmic domain Cys-3 binds to the PKM2
C-domain at Cys-474. The PKM2 Cys-474 residue is found in the
M1, but not the R or L, isoform and is conserved among other
mammalian species. PKM1 and PKM2 differ by the presence in
PKM2 of a 56 aa region (aa 378–434) that forms the FBP-binding
allosteric pocket [7]. PKM2 Cys-474 thus resides outside the FBP-
binding site and the inhibitory Lys-433 residue [8]. Nonetheless,
PKM2 Cys-474 is positioned on the PKM2 surface (Fig. S2).
Other work has shown that the Oct-4 transcription factor binds to
the PKM2 C-domain; however, the effect of that interaction on
PKM2 activity was not assessed in those studies [25]. Recent
studies have also shown that PKM2 also interacts with HIF-1a in
the absence of an effect on PKM2 enzymatic activity and is
hydroxylated by PHD3 at Pro-403 in the C-domain [26]. Our
findings lend support to the importance of the PKM2 Cys-474
residue in protein binding and, in turn, the regulation of PKM2
activity.
MUC1-C cytoplasmic domain positively and negatively
regulates PKM2 activity
The present results show that direct binding of MUC1-CD to
recombinant PKM2 in vitro increases PKM2 activity. Addition of
FBP to recombinant PKM2 stimulated PKM2 activity and
MUC1-CD induced an additive increase. To search for supportive
evidence, we incubated PKM2 with a MUC1-CD-derived
peptide, designated GO-203, that contains the MUC1-CD Cys-
3 residue. As found with MUC1-CD, GO-203 stimulated PKM2
activity and this effect was additive with FBP. Notably, GO-203-
induced stimulation of PKM2 activity was abrogated by mutation
of PKM2 Cys-474, indicating that the direct interaction with this
site is responsible for PKM2 activation. Conversely, the present
results demonstrate that MUC1-CD also functions as a negative
regulator of PKM2 activity. Phosphorylation of PKM2 on Tyr-
105 by fibroblast growth factor receptor type 1 is associated with
inhibition of PKM2 activity [9]. Bcr-Abl, JAK2 and FLT3 also
downregulate PKM2 by phosphorylation of the Tyr-105 site [9].
Our results in rat fibroblasts and in human breast cancer cells
demonstrate that MUC1-C has no effect on PKM2 Tyr-105
phosphorylation. Other work has shown that binding of
phosphotyrosine peptides to PKM2 Lys-433 results in release of
FBP and thereby inhibition of PKM2 activity [8]. The MUC1-C
cytoplasmic domain contains a YEKV motif that is phosphory-
lated by EGFR [21,27] and corresponds to phosphotyrosine
peptides that inhibit PKM2 [8]. For that reason, we asked if
EGFR-phosphorylated MUC1-CD binds to the PKM2 C-domain
Lys-433. To directly address this possibility, we mutated MUC1-
CD Cys-3 to block binding to the PKM2 C-domain Cys-474.
Figure 9. Effects of MUC1 on glycolysis and PKM2 activity are attenuated by the C3A mutation. A. Lysates from HCT116 cells stably
expressing an empty vector, wild-type MUC1 or MUC1(C3A) were immunoblotted with the indicated antibodies. B. The indicated cells were analyzed
for glucose uptake. The results (mean6SD of three separate experiments each performed in triplicate) are expressed as nmol/106 cells. C. The
indicated cells were analyzed for lactate production. The results (mean6SD of three separate experiments each performed in triplicate) are expressed
as relative lactate production compared to that in cells expressing the empty vector (assigned a value of 1). D. Lysates from the indicated cells were
analyzed for PKM2 activity. The results (mean6SD of three separate experiments each performed in triplicate) are expressed as relative PKM2 activity
compared to that obtained in cells expressing the empty vector (assigned a value of 1). E. The indicated cells were plated in soft agar and colonies
were counted after incubation for 14 days. The results (mean6SD of two separate experiments each performed in triplicate) are expressed as the
colony number relative to that obtained with HCT116/vector cells (assigned a value of 1).
doi:10.1371/journal.pone.0028234.g009
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MUC1-CD(C3A) exhibited specific binding to the PKM2 C-
domain that was attenuated by mutation of Lys-433. EGFR-
phosphorylated MUC1-CD(C3A) also inhibited PKM2 activity.
As further evidence, a smaller phospho-YEKV peptide devoid of
the Cys-3 residue similarly inhibited PKM2 by a Lys-433-
dependent mechanism. In concert with previous results [8],
binding of EGFR-phosphorylated MUC1-CD(C3A) or the
phospho-YEKV peptide to PKM2 blocked FBP-induced activity.
By contrast, activation of PKM2 by GO-203 binding to Cys-474
was unaffected by the phospho-YEKV peptide. These findings
indicate that MUC1-CD activates PKM2 through the Cys-474 site
and inhibits PKM2 by phosphotyrosine peptide binding to Lys-
433.
Why would MUC1-C play a role in the regulation of
aerobic glycolysis and PKM2 activity?
The present studies further indicate that MUC1-C stimulates or
suppresses PKM2 activity in breast cancer cells by a mechanism
associated with tyrosine phosphorylation of the MUC1-C
cytoplasmic domain. In this context, EGF stimulation induced
phosphorylation of the MUC1-C cytoplasmic domain on tyrosine
and suppressed PKM2 activity by a MUC1-C-dependent
mechanism. These results are in concert with inhibition of
PKM2 activity by binding of the EGFR-phosphorylated MUC1-
C cytoplasmic domain. Nonetheless, given the diversity of signals
that are induced by EGFR activation, including regulation of the
pentose phosphate pathway in glycolysis, these results do not
exclude the possibility that MUC1-C suppresses PKM2 activity by
another mechanism. Arguably, as noted above, MUC1-C could
bind to the PKM2 B-domain Cys-165 and function as an adapter
to facilitate an interaction between c-Src and PKM2. In this
regard, phosphorylation of the MUC1-C cytoplasmic domain on
the YEKV motif in turn functions as a binding site for the c-Src
SH2 domain [27]. The available evidence indicates that MUC1-C
functions physiologically in signaling stress at the apical border of
normal epithelial cells that interface with the external environment
[11]. In the epithelial stress response with reversible loss of
polarity, apical cell surface proteins, such as MUC1-C, can
transiently form complexes with activated receptor tyrosine kinases
to promote proliferation and repair of the epithelial layer [11]. In
carcinoma cells with irreversible loss of polarity, the MUC1-C
subunit constitutively interacts with EGFR and promotes EGFR
signaling [12]. Therefore, it is formally possible that an EGFR-
mediated proliferative response involving overexpression of the
MUC1-C subunit has been appropriated and subverted by cancer
cells to promote their own growth and survival. The overexpres-
sion of MUC1-C is sufficient to induce transformation [13,14] and
resistance to cell death [28,29,30,31]. Cancer cells could thus
conceivably exploit MUC1-C-mediated regulation of aerobic
glycolysis and PKM2 to divert glycolytic metabolites for tumor
cell growth and survival. Alternatively, it is also conceivable that
binding of MUC1-C to the PKM2 Cys-474 may under certain
metabolic conditions be functionally important in activating
PKM2 for the increased production of pyruvate and thereby (i)
ATP through the TCA cycle, and (ii) acetyl-CoA and lipid
synthesis. For example, the redox state of the cancer cell could
affect reactivity of the MUC1-C Cys-3 residue and thereby dictate
whether MUC1-C binds to PKM2 Cys-474 and induces PKM2
activity. Thus, further studies will be needed that address the
effects of MUC1-C on the pentose phosphate pathway, glucose-
derived lipid biosynthesis, oxygen consumption and ATP produc-
tion in cancer cells. In summary, the present findings demonstrate
that MUC1-C stimulates aerobic glycolysis and that this response
may be mediated, at least in part, by both activation of the Akt
pathway and interactions with PKM2.
Materials and Methods
Cell culture
Rat 3Y1/vector and 3Y1/MUC1-CD cells [14] were cultured
in DMEM medium containing 10% heat-inactivated fetal bovine
serum (FBS), 100 units/ml penicillin, 100 mg/ml streptomycin
and 2 mM L-glutamine. Human ZR-75-1, MCF-7 (ATCC,
Manassas, VA), ZR-75-1/vector, ZR-75-1/MUC1siRNA [32],
MCF-7/vector and MCF-7/MUC1siRNA [33] breast cancer cells
were grown in RPMI1640 medium with 10% FBS, antibiotics and
L-glutamine. Human HCT116 colon cancer cells were cultured in
Dulbecco’s modified Eagle’s medium with 10% FBS and
antibiotics [20]. Cells were transiently transfected with control,
Akt siRNA and MUC1 siRNA pools (Dharmacon, Lafayette, CO)
in the presence of Lipofectamine (Invitrogen, Carlsbad, CA). In
certain studies, cells were cultured with 0.1% FBS for 24 h and
then stimulated with 10 ng/ml EGF (Sigma, St. Louis, MO).
Glucose uptake and lactate production
Cells (10
5/60 mm culture dish) were seeded for 24 h and the
culture supernatant was then replaced with 5 ml of FBS-free and
L-glutamine-free medium. After incubation for 8 h, the superna-
tant was collected, centrifuged and stored at 280uC. Glucose
uptake was measured using the Amplex Red Glucose/Glucose
Oxidase Assay Kit (Molecular Probes, Carlsbad, CA). Lactate
production was measured by the Lactate Assay Kit (BioVision,
Mountain View, CA).
Pyruvate kinase assay
Pyruvate kinase activity was measured using the Pyruvate Kinase
Assay Kit (BioVision). The assays were performed with 1 mg of cell
lysate prepared as described [29]. Alternatively, 5 mM recombi-
nant His-PKM2 was incubated in the absence and presence of
MUC1-CD, FBP (Sigma), GO-203, CP-2, TDRSPpYEKVSA or
TDRSPYEKVSA peptide for 30 min at room temperature and
then assayed for activity. The results were determined from three to
five separate experiments each performed in triplicate.
Immunoprecipitation and immunoblotting
Lysates from subconfluent cells were prepared as described [29].
Soluble proteins were precipitated with anti-PKM2 (Cell Signaling
Technology, Danvers, MA) and anti-MUC1-C (Ab5; NeoMarkers,
Fremont, CA). The precipitates and cell lysates were immuno-
blotted with anti-MUC1-C, anti-PKM2, anti-p-PKM2(Tyr-105),
anti-p-Tyr (Cell Signaling Technology) and anti-b-actin (Sigma).
Immune complexes were detected with horseradish peroxidase-
conjugated secondary antibodies and enhanced chemiluminescence
(GE Healthcare Biosciences, Salt Lake City, UT).
In vitro binding assays
Human PKM2 was cloned into pET28a (EMD Chemicals,
Gibbstown, NJ) to express an N-terminal His-tagged fusion
protein. Recombinant PKM2 and PKM2 deletion mutants were
purified from E. coli using Ni-agarose beads (Qiagen, Valencia,
CA). GST, GST-MUC1-CD, GST-MUC1-CD(1-45), GST-
MUC1-CD(46-72) and GST-MUC1-CD with specific point
mutations were prepared as described [32]. Purified GST-
MUC1-CD proteins bound to glutathione beads were incubated
with 10 units EGFR (Sigma) in the presence of 200 mM ATP for
30 min at 30uC. Adsorbates to glutathione-conjugated beads were
analyzed by immunoblotting. In certain experiments, phosphor-
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GST moiety.
Colony formation assays
Soft agar colony formation assays were performed in medium
containing 25 mM glucose supplemented with 10% FBS. Six-well
plates were coated with 1.5 ml of 0.6% base medium agar. Cells
were plated at a density of 1610
4 cells/well with 1.5 ml of 0.35%
top medium agar. The cultures were incubated for 14 days.
Colonies were stained with crystal violet and counted.
Confocal microscopy
3Y1/vector and 3Y1/MUC1-CD cells were cultured on glass
coverslips in 60 mm dishes. For staining mitochondria, the cells
were incubated in serum-free medium containing 100 nM of
MitoTracker Red CMXRos (Molecular Probes, Eugene, OR) for
30 min at 37uC. The cells were then washed with complete
medium containing serum, pre-fixed with 3.7% formaldehyde for
15 min at 37uC, and permeabilized in 1% bovine serum albumin
(BSA)–supplemented PBS containing 0.2% Triton X-100 for
5 min at 25uC. Post-fixation was done in 3.7% formaldehyde/PBS
for 5 min at 25uC. The fixed cells were washed in PBS and then
blocked with a mixture of 2% BSA and 5% nonfat milk for 1 hour
at 25uC. The fixed and blocked cells were incubated with anti–
PKM2 antibody (Abcam) overnight at 4uC, followed by incubation
with ‘Alexa-Fluor 647’ anti-rabbit IgG secondary antibody
(Invitrogen). Nuclei were stained with 49, 6-diamidino-2-pheny-
lindole (DAPI, 1 mg/ml; Invitrogen). After mounting the
coverslips, images were captured with a Yokogawa spinning disk
confocal microscope.
Supporting Information
Figure S1 Subcellular distribution of PKM2 in 3Y1/
vector and 3Y1/MUC1-CD cells. Confocal microscopy of
3Y1/vector and 3Y1/MUC1-CD cells stained with anti-PKM2
antibody. Mitochondria were stained with MitoTracker Red.
Nuclei were stained with DAPI.
(TIF)
Figure S2 Structural model for PKM2 highlighting the
B-domain Cys-165 and C-domain Cys-474 sites. View of
the PKM2 monomer structure with the colored A- (blue), B-
(green), C- (pink) and D- (brown) domains. Residues Cys-165, Cys-
474 and Lys-433 are presented in a space-filling model.
(TIF)
Acknowledgments
The authors thank Dr. L. Cantley for providing the His-PKM2 vector.
Author Contributions
Conceived and designed the experiments: MK RA DK. Performed the
experiments: MK RA MA YU. Analyzed the data: MK RA MA YU.
Wrote the paper: DK.
References
1. Warburg O (1956) On the origin of cancer cells. Science 123: 309–314.
2. Majumder PK, Febbo PG, Bikoff R, Berger R, Xue Q, et al. (2004) mTOR
inhibition reverses Akt-dependent prostate intraepithelial neoplasia through
regulation of apoptotic and HIF-1-dependent pathways. Nat Med 10: 594–601.
3. Altenberg B, Greulich KO (2004) Genes of glycolysis are ubiquitously
overexpressed in 24 cancer classes. Genomics 84: 1014–1020.
4. Mazurek S, Boschek CB, Hugo F, Eigenbrodt E (2005) Pyruvate kinase type M2
and its role in tumor growth and spreading. Semin Cancer Biol 15: 300–308.
5. Monteys AM, Spengler RM, Wan J, Tecedor L, Lennox KA, et al. (2010)
Structure and activity of putative intronic miRNA promoters. RNA 16:
495–505.
6. Christofk HR, Vander Heiden MG, Harris MH, Ramanathan A, Gerszten RE,
et al. (2008) The M2 splice isoform of pyruvate kinase is important for cancer
metabolism and tumour growth. Nature 452: 230–233.
7. Dombrauckas JD, Santarsiero BD, Mesecar AD (2005) Structural basis for
tumor pyruvate kinase M2 allosteric regulation and catalysis. Biochemistry 44:
9417–9429.
8. Christofk HR, Vander Heiden MG, Wu N, Asara JM, Cantley LC (2008)
Pyruvate kinase M2 is a phosphotyrosine-binding protein. Nature 452: 181–186.
9. Hitosugi T, Kang S, Vander Heiden MG, Chung TW, Elf S, et al. (2009)
Tyrosine phosphorylation inhibits PKM2 to promote the Warburg effect and
tumor growth. Sci Signal 2: ra73.
10. Mazurek S, Boschek CB, Eigenbrodt E (1997) The role of phosphometabolites in
cell proliferation, energy metabolism, and tumor therapy. J Bioenerg Biomembr
29: 315–330.
11. Kufe D (2009) Mucins in cancer: function, prognosis and therapy. Nature
Reviews Cancer 9: 874–885.
12. Ramasamy S, Duraisamy S, Barbashov S, Kawano T, Kharbanda S, et al.
(2007) The MUC1 and galectin-3 oncoproteins function in a microRNA-
dependent regulatory loop. Mol Cell 27: 992–1004.
13. Li Y, Liu D, Chen D, Kharbanda S, Kufe D (2003) Human DF3/MUC1
carcinoma-associated protein functions as an oncogene. Oncogene 22:
6107–6110.
14. Huang L, Chen D, Liu D, Yin L, Kharbanda S, et al. (2005) MUC1 oncoprotein
blocks GSK3b-mediated phosphorylation and degradation of b-catenin. Cancer
Res 65: 10413–10422.
15. Khodarev N, Pitroda S, Beckett M, MacDermed D, Huang L, et al. (2009)
MUC1-induced transcriptional programs associated with tumorigenesis predict
outcome in breast and lung cancer. Cancer Res 69: 2833–2837.
16. MacDermed DM, Khodarev NN, Pitroda SP, Edwards DC, Pelizzari CA, et al.
(2010) MUC1-associated proliferation signature predicts outcomes in lung
adenocarcinoma patients. BMC Medical Genomics 3: 16.
17. Pitroda S, Khodarev N, Beckett M, Kufe D, Weichselbaum R (2009) MUC1-
induced alterations in a lipid metabolic gene network predict response of human
breast cancers to tamoxifen treatment. Proc Natl Acad Sci USA 106:
5837–5841.
18. Raina D, Kharbanda S, Kufe D (2004) The MUC1 oncoprotein activates the
anti-apoptotic PI3K/Akt and Bcl-xL pathways in rat 3Y1 fibroblasts. J Biol
Chem 279: 20607–20612.
19. Raina D, Kosugi M, Ahmad R, Panchamoorthy G, Rajabi H, et al. (2011)
Dependence on the MUC1-C oncoprotein in non-small cell lung cancer cells.
Mol Cancer Therapeutics 10: 806–816.
20. Leng Y, Cao C, Ren J, Huang L, Chen D, et al. (2007) Nuclear import of the
MUC1-C oncoprotein is mediated by nucleoporin Nup62. J Biol Chem 282:
19321–19330.
21. Li Y, Ren J, Yu W, Li G, Kuwahara H, et al. (2001) The EGF receptor regulates
interaction of the human DF3/MUC1 carcinoma antigen with c-Src and b-
catenin. J Biol Chem 276: 35239–35242.
22. Vander Heiden MG, Cantley LC, Thompson CB (2009) Understanding the
Warburg effect: the metabolic requirements of cell proliferation. Science 324:
1029–1033.
23. Levine AJ, Puzio-Kuter AM (2010) The control of the metabolic switch in
cancers by oncogenes and tumor suppressor genes. Science 330: 1340–1344.
24. Deberardinis RJ, Sayed N, Ditsworth D, Thompson CB (2008) Brick by brick:
metabolism and tumor cell growth. Curr Opin Genet Dev 18: 54–61.
25. Lee J, Kim HK, Han YM, Kim J (2008) Pyruvate kinase isozyme type M2
(PKM2) interacts and cooperates with Oct-4 in regulating transcription.
Int J Biochem Cell Biol 40: 1043–1054.
26. Luo W, Hu H, Chang R, Zhong J, Knabel M, et al. (2011) Pyruvate Kinase M2
Is a PHD3-Stimulated Coactivator for Hypoxia-Inducible Factor 1. Cell 145:
732–744.
27. Li Y, Kuwahara H, Ren J, Wen G, Kufe D (2001) The c-Src tyrosine kinase
regulates signaling of the human DF3/MUC1 carcinoma-associated antigen
with GSK3b and b-catenin. J Biol Chem 276: 6061–6064.
28. Yin L, Kufe D (2003) Human MUC1 carcinoma antigen regulates intracellular
oxidant levels and the apoptotic response to oxidative stress. J Biol Chem 278:
35458–35464.
29. Ren J, Agata N, Chen D, Li Y, Yu W-H, et al. (2004) Human MUC1
carcinoma-associated protein confers resistance to genotoxic anti-cancer agents.
Cancer Cell 5: 163–175.
30. Yin L, Kharbanda S, Kufe D (2007) Mucin 1 oncoprotein blocks hypoxia-
inducible factor 1 alpha activation in a survival response to hypoxia. J Biol Chem
282: 257–266.
31. Yin L, Kharbanda S, Kufe D (2009) MUC1 oncoprotein promotes autophagy in
a survival response to glucose deprivation. Int J Oncol 34: 1691–1699.
MUC1-C Regulates Glycolysis and PKM2
PLoS ONE | www.plosone.org 13 November 2011 | Volume 6 | Issue 11 | e2823432. Ahmad R, Raina D, Joshi MD, Kawano T, Kharbanda S, et al. (2009) MUC1-
C oncoprotein functions as a direct activator of the NF-kB p65 transcription
factor. Cancer Res 69: 7013–7021.
33. Ahmad R, Raina D, Trivedi V, Ren J, Rajabi H, et al. (2007) MUC1
oncoprotein activates the IkB kinase b complex and constitutive NF-kB
signaling. Nat Cell Biol 9: 1419–1427.
MUC1-C Regulates Glycolysis and PKM2
PLoS ONE | www.plosone.org 14 November 2011 | Volume 6 | Issue 11 | e28234